Navigation Links
InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma
Date:3/3/2010

For diagnostic and monoclonal antibody production, Zap-Hybridoma improves target antibody purity and hybridoma productivity.

Fort Collins, CO (PRWEB) March 3, 2010 -- InVitria’s launch of Zap-Hybridoma provides a powerful solution for hybridoma cell culture. Zap-Hybridoma was created to improve monoclonal antibody productivity and deliver easier purification of the target product.

Zap-Hybridoma was developed by InVitria’s Cell Culture Development team as an answer to many of the challenges facing scientists working with hybridoma cell culture. “Not only can Zap-Hybridoma increase productivity, it delivers consistent results and allows hybridoma cells to more quickly adapt away from FBS (fetal bovine serum),” said Dr. Steve Pettit, InVitria’s Director of Cell Culture Development. “We tested Zap-Hybridoma in six of the leading commercial hybridoma media on the market today and observed faster cell growth, a 50% average increase in maximum cell density and increased monoclonal antibody yield when compared to the recommended use of the manufacturer.”

“Zap-Hybridoma is an innovation InVitria is proud to bring to its customers so they can achieve better performance more consistently,” said Scott Deeter, InVitria President and CEO. "We developed Zap-Hybridoma to give users an IgG free alternative to FBS without sacrificing performance.”
                                                                                                                                                                                
Zap-Hybridoma / FBS
IgG Free                                                                                YES / NO
Consistent Performance                                                    YES / NO
Defined & Animal Component-Free                                YES / NO
Accelerates Adaptation to Serum-Free Media                YES / NO
Lowers Operating & Capital Costs                                   YES / NO
   
To order your sample of Zap-Hybridoma or to receive more information, please visit Zap-Hybridoma.

About InVitria – InVitria.com
InVitria specializes in cell culture media optimization for the biotechnology industry. InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria’s product solutions, e-mail info(at)InVitria(dot)com or call 1-800-916-8311.

###

Read the full story at http://www.prweb.com/releases/ZapHybridoma/InVitria/prweb3678694.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. InVitria Sponsors 2010 Biomanufacturing Summit
2. Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance
3. InVitrias Better Ingredients for Better Media to be Showcased at BPI 09
4. InVitria Reveals Technology to Optimize Hybridoma Production Performance
5. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
6. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
7. InVitrias Cellastim Delivers Superior Results in Mammalian Cell Culture
8. InVitria Touts Product Advantages at Cambridges Cell Culture Conference
9. InVitria Sponsors Cambridge Healthtechs Optimizing Cell Culture Development Conference
10. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
11. InVitria Expands Sales Team
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma  
(Date:12/2/2016)... More than $4.3 million was raised last night ... ). The gala was held at the American Museum of ... and honored Alan Alda and P. ... medicine and the public understanding of science. Since the first ... has raised $40 million for the Laboratory,s research and education ...
(Date:12/2/2016)... LOS ANGELES , Dec. 2, 2016 ... research and development company specializing in oncology, today announced ... a noted sarcoma surgeon, industry consultant, and private healthcare ... Brien is a healthcare leader with clinical and strategic ... Kriegsman , CytRx,s Chairman and CEO. "As one of ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 01, 2016 , ... ... event is expanding to three days and will take place on February 1-3, 2017 ... (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which ...
Breaking Biology Technology:
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):